

Examiner Ebenezer Sackey  
 U.S. 10/618,578  
 Group Art Unit 3792  
 Page 2

# IN THE SPECIFICATION

Please insert the following after paragraph [0006] (Summary of the Invention):

## **-BRIEF DESCRIPTION OF THE DRAWINGS**

FIG. 1a is a graphical representation showing the migration of PGM from the glycolysis enzyme complex into the transaminase complex.

FIG. 1b is a graphical representation showing the effect of aminoacetate (AOA) and hydroxylamine (HA) on the activity of the cytosolic and mitochondrial isoenzyme of the GOT in vitro.

FIG. 2a is the structural formula of 5-methyl-*N*-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide.

FIG. 2b is the structural formula of (2*Z*)-2-cyano-3-hydroxy-*N*-[4-(trifluoromethyl)phenyl]but-2-enamide.

FIG. 2c is the structural formula of *N*-(3,5-dihalogenophenyl)-5-methylisoxazole-4-carboxamide.

FIG. 2d is the structural formula (2*Z*)-2-cyano-*N*-(3,5-dihalogenophenyl)-3-hydroxybut-2-enamide.

FIG. 2e is the structural formula of 5-methyl-*N*-[4-(trihalogenomethoxy)phenyl]isoxazole-4-carboxamide.

FIG. 2f is the structural formula of (2*Z*)-2-cyano-3-hydroxy-*N*-[4-(trihalogenomethoxy)phenyl]but-2-enamide.

FIG. 2g is the structural formula of *N*-(3-halogenophenyl)-5-methylisoxazole-4-carboxamide.

FIG. 2h is the structural formula of (2*Z*)-2-cyano-*N*-(3-halogenophenyl)-3-hydroxybut-2-enamide.

FIG. 3a is the structural formula of methyl 4-cyano-4-oxobutanoate.

Examiner Ebenezer Sackey  
U.S. 10/618,578  
Group Art Unit 3792  
Page 3

FIG. 3b is the structural formula of ethyl 4-cyano-4-oxobutanoate.

FIG. 3c is the structural formula of methyl 5-cyano-5-oxopentanoate.

FIG. 3d is the structural formula of ethyl 5-cyano-5-oxopentanoate.

FIG. 3e is the structural formula of methyl 5-cyano-3-methyl-5-oxopentanoate.

FIG. 3f is the structural formula of ethyl 5-cyano-3-methyl-5-oxopentanoate.

FIG. 3g is the structural formula of methyl 6-cyano-6-oxohexanoate.

FIG. 3h is the structural formula of ethyl 6-cyano-6-oxohexanoate.

FIG. 4a is the structural formula of methyl 4-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]-4-oxobutanoate.

FIG. 4b is the structural formula of methyl 5-[(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)oxy]-5-oxopentanoate.

FIG. 4c is the structural formula of 2-oxo-5-phenylpentanenitrile.

FIG. 5a is the structural formula of (aminooxy)acetic acid.

FIG. 5b is the structural formula of (aminooxy)acetaldehyde.

FIG. 5c is the structural formula of 2-(aminooxy)ethanol.

FIG. 5d is the structural formula of *O*-methylhydroxylamine.

FIG. 5e is the structural formula of hydroxylamine.

FIG. 5f is the structural formula of glycol acid.

FIG. 5g is the structural formula of glycolaldehyde.

FIG. 5h is the structural formula of ethylene glycol.

FIG. 5i is the structural formula of acetaldehyde.

FIG. 6a is the structural formula of 1-(aminooxy)methanesulfonamide.

FIG. 6b is the structural formula of 1-(aminooxy)-*N*-phenylmethanesulfonamide.

FIG. 6c is the structural formula of (carboxymethoxy)ammonium.

FIG. 6d is the structural formula of (aminooxy)acetate.

FIG. 6e is the structural formula of *O*-ethylhydroxylamine.

FIG. 6f is the structural formula of *O*-methylhydroxylamine--

Examiner Ebenezer Sackey  
U.S. 10/618,578  
Group Art Unit 3792  
Page 4

Please amend paragraph [0043] as follows:

--Various substances which can be used according to the invention are shown in the further figures, FIGS. 2a-2h, 3a-3h, 4a-4c, 5a-5i, and 6a-6f. In particular, the essential variation possibilities are represented in an exemplary manner, the permutations which are easily deduced not being shown for the sake of simplicity. The invention finally also comprises all natural metabolites of the described substances.--